Trial · NCT03224104
Results by group23
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 23
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) | Group A - TG02 + Radiotherapy (RT) | 150 | mg | ||
| Maximum Tolerated Dose (MTD) | Group B - TG02 + Temozolomide (TMZ) | 150 | mg | ||
| Percentage of Participants Maintaining Progression-free Survival at 6 Months (PFS-6) | Group C - TG02 | 6.7 | 80% Confidence Interval 2.5 to 14.3 | percentage of participants | |
| Progression-free Survival | Group A - TG02 + RT - 100 mg | 2.4 | 95% Confidence Interval 1.8 to 2.4 | Months | |
| Progression-free Survival | Group A - TG02 + RT - 150 mg | 4.4 | 95% Confidence Interval 1.4 to 6.7 | Months | |
| Progression-free Survival | Group B - TG02 + TMZ - 100 mg | 4.9 | 95% Confidence Interval 2.6 to 4.9 | Months | |
| Progression-free Survival | Group B - TG02 + TMZ - 150 mg | 7.1 | 95% Confidence Interval 4.6 to 7.1 | Months | |
| Progression-free Survival | Group C - TG02 | 1.87 | 95% Confidence Interval 1.64 to 1.94 | Months | |
| Overall Survival (OS) | Group A - TG02 + RT - 100 mg | 9.3 | 95% Confidence Interval 1.8 to 9.3 | Months | |
| Overall Survival (OS) | Group A - TG02 + RT - 150 mg | 6.7 | 95% Confidence Interval 4.4 to 6.7 | Months | |
| Overall Survival (OS) | Group B - TG02 + TMZ - 100 mg | 14.6 | 95% Confidence Interval 6.3 to 14.6 | Months | |
| Overall Survival (OS) | Group B - TG02 + TMZ - 150 mg | 11.3 | 95% Confidence Interval 5.6 to 11.3 | Months | |
| Overall Survival (OS) | Group C - TG02 | 7.00 | 95% Confidence Interval 4.90 to 8.84 | Months | |
| Objective Response | Group A - TG02 + RT - 100 mg | 0 | Number of participants | ||
| Objective Response | Group A - TG02 + RT - 150 mg | 0 | Number of participants | ||
| Objective Response | Group B - TG02 + TMZ - 100 mg | 0 | Number of participants | ||
| Objective Response | Group B - TG02 + TMZ - 150 mg | 3 | Number of participants | ||
| Objective Response | Group C - TG02 | 1 | Number of participants | ||
| Neurological Progression-free Survival | Group A - TG02 + RT - 100 mg | 8.4 | 95% Confidence Interval 1.8 to 8.4 | Months | |
| Neurological Progression-free Survival | Group A - TG02 + RT - 150 mg | 6.5 | 95% Confidence Interval 1.6 to 8.1 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03224104/results